elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Etoposide
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Etoposide
RIS
0.001
(Research Intensity Score)
Papers
72
Top papers
Small Cell Lung Cancer
2025 · 158 citations
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
2023 · 351 citations
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · 2262 citations
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
2024 · 140 citations
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · 695 citations
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
2020 · 766 citations
Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics
2025 · 27 citations
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System
2022 · 98 citations
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 · 2333 citations
Newest papers
Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209)
2026
Collateral sensitivities with predictive signatures emerge in a novel model of evolved chemoresistance in osteosarcoma
2026
Surgical resection of a PET-positive residual mass following curative-intent chemotherapy for a giant intra-abdominal seminoma: a case report
2026
Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report
2026
Small intestine choriocarcinoma with brain, lung and liver metastases in a male patient: a case report
2026
Severe multiorgan toxicities after the first cycle of standard-dose etoposide–cisplatin therapy for metastatic nonseminoma successfully managed with etoposide–carboplatin: a case report
2026 · 1 citations
Lactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy
2026
Remarkable Response to Etoposide and Cisplatin in Aggressive-Variant Prostate Cancer With Low Prostate-Specific Antigen Levels: A Case Report
2026
Small Cell Lung Cancer
2025 · 158 citations
Browse all papers →
Etoposide's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Etoposide's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link